Article

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 09/2010; 54(9):4016-9. DOI: 10.1128/AAC.00100-10
Source: PubMed

ABSTRACT We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC(50)s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.

Download full-text

Full-text

Available from: Dominique Rousset, Jul 06, 2015
0 Followers
 · 
142 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The world's ageing population and prevalence of chronic diseases have lead to high demand for tele-home healthcare, in which vital-signs monitoring is essential. An overview of state-of-art wearable technologies for remote patient-monitoring is presented, followed by case studies on a cuffless blood pressure meter, ring-type heart rate monitor, and Bluetoothtrade mark-based ECG monitor. Aim of our project is to develop a tele-home healthcare system which utilizes wearable devices, wireless communication technologies, and multisensor data fusion methods. As an important part of this system, a cuffless BP meter has been developed and tested on 30 subjects in a total of 71 trials over a period of five months. Preliminary results show a mean error (ME) of 1.82 mmHg and standard deviation of error (SDE) of 7.62 mmHg in systolic pressure; while ME and SDE in diastolic pressure are 0.45 mmHg and 5.27 mmHg, respectively.
    Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 02/2004; 7:5384-7. DOI:10.1109/IEMBS.2004.1404503
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-1 group O (HIV-O) is characterized by a high genetic divergence from HIV-1 group M viruses. Little is known about the therapeutic impact of this diversity. The aim of this study was to assess in a large series of samples (1) the genotypic impact of natural polymorphism of the HIV-O reverse transcriptase and protease genes; and (2) the predictive value of resistance interpretation algorithms developed for HIV-1 group M when used for highly mutated HIV-O viruses. Sixty-eight antiretroviral-naive and 9 highly antiretroviral-experienced HIV-O-infected patients were included. The viruses were sequenced and resistance-associated mutations were identified using 3 different algorithms (Agence Nationale de Recherches sur le SIDA et les hépatites virales, Rega, Stanford). All HIV-O samples naturally exhibited the A98G and V179E resistance mutations in the reverse transcriptase region; 54% of samples presented the Y181C mutation, conferring resistance to nonnucleoside reverse transcriptase inhibitors. Twelve minor resistance mutations, present in more than 75% of the protease sequences, led to the different algorithms giving discrepant results for nelfinavir and saquinavir susceptibility. A marked virological response was observed in 8 of the 9 antiretroviral-experienced patients, despite the prediction of limited activity of the combination for 5 to 8 patients according to the algorithm used. The high level of natural polymorphism in HIV-O genes, and the important discrepancies between genotypic resistance interpretation and the virological response, emphasize the need for resistance algorithm rules better adapted to HIV-O.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 02/2011; 56(2):139-45. DOI:10.1097/QAI.0b013e318201a904 · 4.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The HIV pandemic is caused by viruses of type 1 group M (HIV-M). Beside the majority of these viruses, there are many genetically divergent variants, leading to the definition of HIV-2 and groups N, O and P in HIV-1. HIV-1 groups are the result of independent cross-species of viruses from chimpanzees and gorillas living in Western Central Africa. These simian origins and the necessary adaptation to the human species are the sources of genomic characteristics, phylogenetic and viral properties, specific to each group. The natural history of the infections associated to these variants nevertheless seems similar to that of HIV-M, with a high viral replication in vivo associated with immunosuppression. These non-M variants have all been described for the first time in patients of Cameroonian origin. The Western Central Africa is the epicenter of the epidemics of non-M variants, and the diffusion outside this area is anecdotal, except in France. In Cameroon, the origin of all groups currently described, HIV-O infections account for 1% of HIV infections, while only 15 cases of HIV-N infections and two HIV-P infections have been reported to date. If the important genetic diversity of these variants requires the use of specific tools for serological identification and molecular characterization, diagnosis and virological monitoring of these infections now appear possible with current commercial kits; however, very little data are available on the response to antiretroviral therapy and no recommendations are defined in case of failure. Despite improved knowledge of these rare variants, many fascinating questions persist about their origin, genetic evolution and reasons for their low epidemiological diffusion. Their discovery and the description of many simian viruses, demonstrates a dynamic transmission to humans, making it likely that there are other variants; we should therefore pursue a health monitoring, especially in front of any discrepancy between screening and therapeutic management of HIV infections.
    09/2011; 13(3). DOI:10.1016/j.antinf.2011.03.009